CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia

M. T. Tayeb, Caroline Clark, Neva Elizabeth Haites, S. N. Payne, H. L. McLeod, Linda Sharp, Patrick Hugh Rooney, Graeme Ian Murray

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Prostate cancer (PRCa) is one of the most common causes of cancer death in men and determinants of PRCa risk remain largely unidentified. Benign prostatic hyperplasia (BPH) is found in the majority of ageing men and has been linked with PRCa. CYP3A4 may influence PRCa through its role in testosterone metabolism. This nested case-control study assessed a CYP3A4 single nucleotide polymorphism as a risk factor for developing PRCa in patients with BPH. The CYP3A4 variant allele identified men with BPH who are at increased risk of progressing to PRCa (odds ratio 6.3, 95% Cl 2.3-17.3), providing a potential tool to assist prediction strategies for this disease.

Original languageEnglish
Pages (from-to)653-655
Number of pages2
JournalOncology Reports
Volume9
Issue number3
Publication statusPublished - 2002

Keywords

  • CYP3A4
  • prostate cancer
  • polymorphism
  • benign prostate hyperplasia
  • CLINICAL PRESENTATION
  • GENETIC VARIANT
  • TUMORS

Cite this

Tayeb, M. T., Clark, C., Haites, N. E., Payne, S. N., McLeod, H. L., Sharp, L., Rooney, P. H., & Murray, G. I. (2002). CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncology Reports, 9(3), 653-655.